TKIs are approved for NSCLC especially for cancers expressing mutated EGFR (179, 180), whereas anti-EGFR mAbs are approved for KRAS wild-type colorectal cancer and local regional head and neck cancers (40, 106). Here, KRAS is linked to cancer.